Valeda™

ValedaTM PBM is the first and only FDA-authorized treatment for dry AMD to improve and maintain vision for up to 2 years1*


*The presence of at least 3 medium drusen (>63 μm and ≤125 μm in diameter), or large drusen (>125 μm in diameter), or non-central geographic atrophy.

Valeda™ PBM LIGHTSITE III clinical trial met the predetermined primary efficacy endpoint at Month 212†

84% of Valeda™ PBM–treated patients improved or maintained vision at ~2 years compared to baseline3,4†

More than 60% of Valeda™ PBM–treated patients experienced ≥1-line vision improvement at about 2 years compared to baseline3,4†

† n=98 subjects and 145 eyes

Assessing the Efficacy and Safety of Valeda™ PBM

LIGHTSITE III Pivotal Trial Design

Study design

LIGHTSITE III evaluated the efficacy and safety of Valeda™ PBM in a 24-month, double-masked, sham-controlled, parallel design, prospective, randomized, multi-center trial.4,5


Study population

98 patients (145 eyes) aged ≥50 years with ETDRS BCVA letter score between 50 and 75 and a diagnosis of dry AMD defined by the presence of drusen and/or nonfoveal center GA were randomized at a 2:1 ratio into 2 treatment groups.4

Endpoints

Primary efficacy endpoint: Mean BCVA change from baseline to Month 13 or Month 21. Primary safety endpoint: Mean change from baseline to Month 13 or Month 24.4

No phototoxicity or serious adverse events related to Valeda™ PBM2,4

Consistent safety in multiple clinical trials

0 reports of phototoxicity in 3
LIGHTSITE trials2

of patients did not report
eye pain4

Non-Invasive Treatment.

Dilation free. Anesthesia free. Speculum free. Injection free.4

Treatment regimen consists of 54 applications administrated in 6 courses over 2 years

Valeda™ PBM Uses the Power of Light

Valeda™ PBM applies 3 science-backed wavelengths to upregulate cellular energy production6,7

590 nm

Increases nitric oxide synthesis and vasodilation which can improve local oxygenation and nutrient delivery6

660 nm

Promotes O2 binding (CuB), stimulates metabolic activity (ATP), and inhibits inflammation and cell death7

850 nm

Drives electron transfer (CuA), stimulates metabolic activity (ATP), and inhibits inflammation and cell death7

Valeda™ PBM’s unique mechanism of action works to restore cellular energy production and improve retinal cellular health5

The retina is rich in mitochondria, and mitochondrial dysfunction is a known cause of vision loss in dry AMD.

Cytochrome c oxidase (CcO) is a key photoacceptor in the mitochondrial electron transport chain.

Valeda™ PBM wavelengths activate CcO, enhancing electron transport and mitochondrial adenosine triphosphate (ATP) production, the cell’s major source of energy.

No More Watch and Wait. Treat With Valeda™ PBM​​​​​​​

First and only

Valeda™ PBM is the first and only FDA-authorized treatment for early and intermediate dry AMD1


Improve and maintain vision

84% of Valeda™ PBM–treated patients improved or maintained vision at ~2 years compared to baseline3,4*


A noninvasive treatment

Dilation free, speculum free, anesthesia free, and injection free4